Price:
Scientists atSt. JudeChildren’s Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL). Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. The findings were published today in
The
Lancet Oncology.
Adding the chemotherapy vincristine plus a steroid (originally prednisone, and later dexamethasone) as pulse therapy for childhood ALL has been part of standard care since the 1970s. This is despite their being associated with neuropsychological side effects, neuropathy and other late effects. However, to date studies about the need for prolonged treatment with pulse therapy have been inconclusive.
China Rhyming » Blog Archive » A Very Special Peking Compound, #1 Hsien Yu Hsiang Hutong, c 1930
chinarhyming.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinarhyming.com Daily Mail and Mail on Sunday newspapers.
International collaboration helps refine treatment for childhood leukemia
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Chinese Covid-19 Sinopharm vaccine offers poor protection among elderly, finds study Associated Press Chinese, Covid-19, Sinopharm vaccine, poor protection, elderly
A new study suggests that a Sinopharm vaccine offers poor protection from Covid-19 among the elderly, raising questions for dozens of countries that have given the Chinese company s shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90 per cent under 50 years old developed protective antibodies. But the percentage declined with age, and 50 per cent of those over 80 had none.
The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm s Beijing Institute of Biological Products.